In a major leap toward self-reliance in defense technology, India is set to develop its very own fifth-generation fighter jet—the Advanced Medium Combat Aircraft (AMCA) . In a historic move, Defence Minister Rajnath Singh has approved an innovative execution model for the indigenous stealth fighter programme. This model brings together Hindustan Aeronautics Limited (HAL) and private industry players in a competitive framework, marking a significant shift in how India approaches military aviation manufacturing. This bold initiative comes at a critical time, as China has already fielded two fifth-generation fighters , and reports indicate it will supply 40 J-35 stealth jets to Pakistan . Against this backdrop, fast-tracking the AMCA has become an urgent national security imperative. AMCA: India’s Indigenous Stealth Fighter Dream The AMCA project , spearheaded by the Aeronautical Development Agency (ADA) under the Defence Research and Development Organisation (DRDO) , received its l...
The global biosimilar market is expanding rapidly, with pharmaceutical companies forging strategic alliances to enhance their reach and market share. In a significant development, Dr. Reddy’s Laboratories and China’s Bio-Thera Solutions have signed an agreement to introduce two biosimilars in the Southeast Asian market . This partnership reflects the growing demand for affordable biologic alternatives and strengthens both companies' presence in the global biopharmaceutical landscape . Why This Deal Matters With the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, the demand for biosimilars is soaring. Biologic drugs , while highly effective, are often expensive, creating accessibility challenges in emerging markets like Southeast Asia. This collaboration between Dr. Reddy’s and Bio-Thera aims to bridge this gap by offering cost-effective, high-quality biosimilars . Key Highlights of the Agreement 1. Focus on Two Biosimilar Products Th...